What do we gain from the sixth coronary heart disease drug?
- 29 November 2003
- Vol. 327 (7426) , 1237-1238
- https://doi.org/10.1136/bmj.327.7426.1237
Abstract
Footnotes Competing interests None declared.Keywords
This publication has 7 references indexed in Scilit:
- Coronary heart disease prevention: insights from modelling incremental cost effectivenessBMJ, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Cost Effectiveness of Aspirin, Clopidogrel, or Both for Secondary Prevention of Coronary Heart DiseaseNew England Journal of Medicine, 2002
- Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patientsPublished by Wiley ,2000
- The use of statins: a case of misleading priorities?BMJ, 1997
- UNIVERSAL PRECAUTIONS TO PREVENT HIV TRANSMISSION TO HEALTH-CARE WORKERS - AN ECONOMIC-ANALYSIS1990
- What Do We Gain from the Sixth Stool Guaiac?New England Journal of Medicine, 1975